For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Eutilex Co., Ltd.

USPTO Granted Patents = 20

% Expired Patents = 15.0

EPO Patents = 1

Trademarks = 7

Forward Citations = 34

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Byoung S Kwon (20 out of 26 patents)

Young Ho Kim (8 out of 89 patents)

Seoung-Joo Lee (6 out of 6 patents)

4. Ho-Sik Oh (6 out of 7 patents)

5. Joong Won Lee (6 out of 6 patents)

6. Seung-Joo Lee (4 out of 4 patents)

7. Sun Woo Im (4 out of 6 patents)

8. Hyun Tae Son (4 out of 6 patents)

9. Kwang-Hui Kim (4 out of 5 patents)

10. Don-Gil Lee (4 out of 5 patents)

11. Beom-Kyu Choi (4 out of 5 patents)

12. Kwang Hee Kim (3 out of 21 patents)

13. Insoo Park (3 out of 4 patents)

14. Chungyong Han (3 out of 3 patents)

15. Young-Ho Kim (3 out of 115 patents)

20 patents: Sort by Forward Citations

1. 12331116 - Bispecific epitope binding protein comprising anti-4-1BB antibody and a PD-1 protein or fragments thereof and use thereof (2025-06-17),

2. 12122845 - Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof (2024-10-22),

3. 11951130 - Chimeric antigen receptor that binds HLA-DR and CAR-T cell (2024-04-09),

4. 11859004 - Anti-human 4-1BB antibodies and uses thereof (2024-01-02),

5. 11396555 - Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof (2022-07-26),

6. 11395836 - Cancer antigen specific cytotoxic T cell (2022-07-26),

7. 11072646 - Epitope for switching to T1 cell and use thereof (2021-07-27),

8. 11053298 - Epitope for switching to T2 cell and use thereof (2021-07-06),

9. 11013765 - Chimeric antigen receptor that binds HLA-DR and CAR-T cell (2021-05-25),

10. 10927183 - Anti-human VSIG4 antibodies and uses thereof (2021-02-23),

11. 10919976 - IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof (2021-02-16),

12. 10919972 - Anti-human 4-1BB antibodies and uses thereof (2021-02-16),

13. 10851151 - Epitope for switching to T17 cell and use thereof (2020-12-01),

14. 10774151 - Anti-human 4-1BB antibodies and uses thereof (2020-09-15),

15. 10626183 - IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof (2020-04-21),

Company Overview

Eutilex Co., Ltd. is a biotechnology company based in Seoul, South Korea, specializing in the development of innovative immunotherapies for cancer treatment. The organization focuses on harnessing the power of the immune system to create effective therapeutic solutions, particularly in the field of cancer vaccines and cell therapies. Eutilex is committed to advancing medical science through rigorous research and development, aiming to improve patient outcomes and contribute to the global fight against cancer.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

20 Patents

#230 in Seoul

#635 in South Korea

#31,295 in the World

Seoul, South Korea

Eutilex Co., Ltd.

Forward Citations = 34

46 inventors:

Byoung S Kwon (20 out of 26 patents)

Young Ho Kim (8 out of 89 patents)

Seoung-Joo Lee (6 out of 6 patents)

4. Ho-Sik Oh (6 out of 7 patents)

5. Joong Won Lee (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Eutilex Co., Ltd.. Retrieved from https://idiyas.com/company/eutilex-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…